You are here
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Background: We explored baseline tumor size (BTS) as a prognostic factor in addition to standard prognostic variables for overall survival (OS) in pts with metastatic melanoma treated with MK-3475. Methods: In a phase I clinical trial, 411 pts received MK-3475 2 mg/kg Q3W, 10 mg/kg Q3W, or 10 mg/kg Q2W. Response was assessed every 12 wk by RECIST 1.1 by independent central review. BTS was quantified as the sum of the longest dimensions of all RECIST target lesions. Log-rank, Kaplan-Meier (KM), and Cox proportional hazards regressions were used to identify independent prognostic factors for OS. Cutpoints and combinations of prognostic factors were determined by binary tree analysis. Results: Of the 411 melanoma pts studied, 365 had measurable tumors at baseline and a median follow-up duration of 10 mo as of the 10/18/2013 cutoff date. Median OS was not reached, and 1-y OS was 71% in all 411 pts and 69% in the 365 pts included in this analysis. By univariate analysis, the following traditional factors were associated with OS: elevated LDH, ECOG performance status of 1, and M-stage 1c (Table). BTS (median 97.8 mm, range 10.4-895 mm) was significantly and strongly associated with OS using log-rank tests, Cox models, KM methods, and binary tree analysis. Binary tree analysis provided a cutpoint of 90 mm BTS as an independent factor. While tumor size >90 mm was associated with a worse prognosis, these pts did have a median OS of 14 mo in the combined data set, suggesting they derive benefit from MK-3475. Conclusions: Baseline tumor size is the strongest independent prognostic factor in pts with metastatic melanoma treated with MK3475. If further validated, baseline tumor size could serve as an additional factor when randomizing pts for future clinical trials using anti-PD1 therapies. Clinical trial information: NCT01295827.
|N = 363|
|n||% Alive at 1 Year
|Not M1c||152||75.4 [65.5-85.4]|
|ECOG performance status|
|Baseline tumor size|
Abstracts by Richard Wayne Joseph:
Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.Meeting: 2016 Genitourinary Cancers Symposium | Abstract No: 570Category: Genitourinary Cancer - Renal Cell Cancer
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.Meeting: 2016 ASCO Annual Meeting | Abstract No: LBA4500
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).Meeting: 2016 ASCO Annual Meeting | Abstract No: 104